Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | PLG | P00747 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CPA1 | P15085 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | YAP1 | P46937 | 2/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948662 | 1.00 | LMNA (0.79) | LMNATDP1PLGPRSS1PRSS2 | |
| SCHEMBL5948568 | 1.00 | LMNA (0.79) | LMNATDP1PLGPRSS1PRSS2 | |
| SCHEMBL5948570 | 1.00 | LMNA (0.79) | LMNATDP1PLGPRSS1PRSS2 | |
| SCHEMBL5948486 | 0.89 | LMNA (0.62) | LMNATDP1PLGPRSS1PRSS2 | |
| SCHEMBL5948228 | 0.89 | LMNA (0.62) | LMNATDP1PLGPRSS1PRSS2 | |
| SCHEMBL5948483 | 0.89 | LMNA (0.62) | LMNATDP1PLGPRSS1PRSS2 | |
| SCHEMBL5948232 | 0.89 | LMNA (0.62) | LMNATDP1PLGPRSS1PRSS2 | |
| Nateglinide SCHEMBL1692510 | 0.89 | LMNA (1.00) | LMNATDP1PLGATMKMT2A | |
| Nateglinide SCHEMBL22088 | 0.89 | LMNA (1.00) | LMNATDP1PLGATMKMT2A | |
| Nateglinide SCHEMBL14199702 | 0.89 | LMNA (1.00) | LMNATDP1PLGATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154970-A1 | Alanines compounds, method of preparing them and their use | YANG YUSHE | 2006-07-13 | — | — | US | claimed |
| EP-1591440-A1 | ALANINES COMPOUNDS, METHOD OF PREPARING THEM AND THEIR USE | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2005-11-02 | — | — | EP | claimed |
| US-20060154970-A1 | Alanines compounds, method of preparing them and their use | YANG YUSHE | 2006-07-13 | — | — | US | disclosed |
| EP-1591440-A1 | ALANINES COMPOUNDS, METHOD OF PREPARING THEM AND THEIR USE | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154970-A1 | Alanines compounds, method of preparing them and their use | IAPP, ASNS, GLS2 | LMNA 781/4885TDP1 4010/4885PLG 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.